 
products in the preamble to clarify that although the petition included 
plaque pH data representative of these products, FDA was concluding 
that the available evidence did not support the eligibility of these 
sucralose-based formulations for the health claim. FDA referred to 
these formulations by their specific product names (i.e., SPLENDA 
Granular, and SPLENDA Packet) for the sake of convenience. The 
amendment to Sec.  101.80 provides for the use of the dental caries 
health claim in food l